The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis

The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis

Background. The assessment of organ damage in patients with systemic sclerosis (SSc) is challenging. The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) proposed in 2019 has not been sufficiently studied and requires testing for wider use.The aim of the study was to examine the progres...

Full description

Saved in:
Bibliographic Details
Main Authors: L. P. Ananyeva, V. V. Babak, A. D. Koltakova, O. A. Koneva, O. V. Desinova, M. N. Starovoytova, O. B. Ovsyannikova, R. U. Shayakhmetova
Format: Article
Language:Russian
Published: IMA PRESS LLC 2025-03-01
Series:Научно-практическая ревматология
Subjects:
progressive systemic sclerosis
damage index
sctc-di
Online Access:https://rsp.mediar-press.net/rsp/article/view/3704
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items